H.C. Wainwright raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $405 from $400 and keeps a Buy rating on the shares following the Q4 report. The firm says momentum continues to build supporting Rezdiffra’s potential to treat patients with compensated metabolic dysfunction-associated steatohepatitis cirrhosis. The firm says a “stellar first year of Rezdiffra launch instills a high degree of confidence and conviction in our blockbuster sales trajectory.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Cautious Outlook on Madrigal Pharmaceuticals Amid Potential Overvaluation and Competitive Pressures
- Madrigal’s Financial Vulnerability: Overreliance on Specialty Pharmacies Threatens Revenue Stability
- Madrigal Pharmaceuticals Reports Strong Rezdiffra Sales
- Buy Rating for Madrigal Pharmaceuticals Driven by Strong Financials and Promising Clinical Trial Results
- Madrigal Pharmaceuticals Phase 3 data ‘encouraging,’ says UBS